Official Statistics

Quarterly vaccination coverage statistics for children aged up to 5 years in the UK (COVER programme): January to March 2026

Updated 25 June 2026

Publication date: 25 June 2026

Health Protection Report

Volume 20 Number 6

This report of the cover of vaccination evaluated rapidly (COVER) programme presents quarterly coverage data for children in the UK who reached their first, second, or fifth birthday during the evaluation quarter (January to March 2026).

The full coverage data by country, region, and upper tier local authority (UTLA) is contained in the data tables accompanying this report.

Main points

In comparison with the previous quarter:

• coverage in England measured in children aged 12 months decreased by 0.7 percentage points for the 6-in-1 vaccine; decreased by 1.2 percentage points for the pneumococcal conjugate vaccine (PCV1); decreased by 0.7 percentage points for the rotavirus vaccine; and decreased by 0.3 percentage points for the Meningococcal B (MenB) vaccine.
• coverage in the UK measured in children aged 12 months decreased by 0.7 percentage points for the 6-in-1 vaccine; decreased by 1.1 percentage points for the PCV1 vaccine; decreased by 0.6 percentage points for the rotavirus vaccine; and decreased by 0.3 percentage points for the MenB vaccine
• coverage of the first dose of measles, mumps and rubella (MMR) vaccine measured at 24 months (in children who first became eligible between January 2025 and March 2025) decreased by 0.5 percentage points in England and decreased by 0.4 percentage points in the UK
• coverage of the first dose of MMR measured in children aged 5 years increased by 0.2 percentage points in England, largely reflecting vaccinations delivered in January 2022 to March 2022
• UK coverage for the pre-school booster (dTaP/IPV) increased by 0.7 percentage points and MMR2 increased by 0.1 percentage points, reflecting vaccinations that should have been delivered between May 2024 to July 2024
• both Scotland and Wales exceeded the 95% World Health Organization (WHO) target for coverage for both the 6-in-1 and MMR1 vaccines measured in children aged 5 years
• in England, vaccination coverage varies geographically and is lowest for all antigens in London as well as in more deprived areas
• vaccination coverage measured this quarter remains below peaks in coverage reported in the previous 10-year period, and for a number of antigens, represents a continuation of an ongoing declining trend in coverage

Coverage at 12 months

Compared with the previous quarter, coverage in the UK measured in children aged 12 months:

• decreased by 0.7 percentage points to 90.1% for the 6-in-1 vaccine

• decreased by 1.1 percentage points to 91.4% for the PCV1 vaccine

• decreased by 0.6 percentage points to 88.2% for the rotavirus vaccine

• decreased by 0.3 percentage points to 90.7% for the MenB vaccine

Coverage in England measured in children aged 12 months:

• decreased by 0.7 percentage points to 89.8% for the 6-in-1 vaccine

• decreased by 1.2 percentage points to 91.1% for the PCV1 vaccine

• decreased by 0.7 percentage points to 87.9% for the rotavirus vaccine

• decreased by 0.3 percentage points to 90.4% for the MenB vaccine

Coverage in England excluding London (as this was the region with the lowest coverage) measured in children aged 12 months:

• for the 6-in-1 vaccine was 91.0%, 1.2 percentage points higher than the overall England coverage

• for the PCV1 vaccine was 92.1%, 1.0 percentage point higher than the overall England coverage

• for the rotavirus vaccine was 89.0%, 1.1 percentage points higher than the overall England coverage

• for the MenB vaccine was 91.6%, 1.2 percentage points higher than the overall England coverage

In Scotland and Wales, coverage was above 90% for all antigens at 12 months.

In Northern Ireland, coverage was above 88% for all antigens except for rotavirus, which was 85.7%.

Compared with the previous quarter, 6-in-1 vaccine coverage decreased in all English regions. It decreased by:

• 0.8 percentage points in the East of England

• 1.5 percentage points in London

• 0.7 percentage points in the Midlands

• 0.7 percentage points in the North East and Yorkshire

• 0.3 percentage points in the North West

• 0.4 percentage points in the South East

• 0.6 percentage points in the South West

Coverage varies by geography. Full coverage data by country, NHS England region, UK Health Security Agency (UKHSA) region, and UTLA is contained in the data tables accompanying this report. Coverage for the 6-in-1 vaccine for quarter 4 2025 to 2026 by UTLA measured in children aged 12 months is presented in Figure 1.

Figure 1. Coverage of the 6-in-1 vaccine measured in children aged 12 months in England for quarter 4 2025 to 2026 by UTLA

Source of vaccine coverage data: UK Health Security Agency.

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0 Contains OS data © Crown copyright and database right 2025.

Coverage of the 6-in-1 vaccine measured at 12 months varies by UTLA. The data underlying Figure 1 is available in the accompanying data file.

In England over the last 10 years, coverage of the 6-in-1 vaccine peaked in quarter 3 of 2016 to 2017 at 93.4%, 3.6 percentage points higher than the current quarter coverage of 89.8% (Figure 2a). Coverage of PCV1 peaked in quarter 2 of 2022 to 2023 at 94.1%, 3.0 percentage points higher than the current quarter coverage of 91.1% (Figure 2b). MenB peaked in quarter 3 of 2017 to 2018 at 93.0%, 2.6 percentage points higher than the current quarter coverage of 90.4% (Figure 2c). Rotavirus peaked in quarter 1 of 2020 to 2021 at 90.9%, 3.0 percentage points higher than the current quarter coverage of 87.9% (Figure 2d).

Figure 2a. Coverage of the primary course of the 6-in-1 vaccine in England measured at 12 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026 [note 1]

Note 1: the 5-in-1 (DTaP/IPV/Hib3) vaccine was used prior to August 2017 when it was replaced with the 6-in-1 vaccine (DTaP/IPV/Hib/HepB3). As a result, from quarter 4 of 2018 to 2019, coverage of the 6-in-1 vaccine is reported rather than the 5-in-1.

Figure 2b. Coverage of the PCV vaccine in England measured at 12 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026 [note 2]

Note 2: from quarter 4 (January to March) 2020 to 2021, PCV1 rather than PCV2 is reported to reflect the change in the PCV schedule.

Figure 2c. Coverage of the MenB vaccine in England measured at 12 months between quarter 2 2016 to 2017 and quarter 4 2025 to 2026

Figure 2d. Coverage of the rotavirus vaccine in England measured at 12 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Based on the 2025 index of multiple deprivation (IMD) scores at the UTLA level, in the 30 least deprived UTLAs, coverage of the 6-in-1 decreased by 0.6 percentage points to 92.3%. In comparison, in the 30 most deprived UTLAs, coverage of the 6-in-1 decreased by 0.1 percentage points to 86.1%. This was 6.2 percentage points lower than the 30 least deprived UTLAs. The difference in coverage between these groups has been increasing in the last 6 years, with coverage in the least deprived group remaining relatively stable and coverage in the most deprived group decreasing (Figure 3).

Figure 3. Coverage of the primary course of the 6-in-1 vaccine in the 30 most and least deprived local authorities in England, measured at 12 months

Coverage at 24 months

Compared with the previous quarter, coverage in the UK for children aged 24 months:

• decreased by 0.2 percentage points to 92.6% for the 6-in-1 vaccine

• decreased by 0.4 percentage points to 87.5% for the PCV booster

• decreased by 0.4 percentage points to 87.8% for the MMR1 vaccine

• decreased by 0.4 percentage points to 87.0% for the MenB booster

• decreased by 0.9 percentage points to 86.9% for the Hib/MenC booster

Coverage in England for children aged 24 months:

• decreased by 0.2 percentage points to 92.3% for the 6-in-1 vaccine

• decreased by 0.3 percentage points to 87.1% for the PCV booster

• decreased by 0.5 percentage points to 87.3% for the MMR1 vaccine

• decreased by 0.4 percentage points to 86.5% for the MenB booster

• decreased by 0.9 percentage points to 86.5% for the Hib/MenC booster

Coverage in England excluding London (as this was the region with the lowest coverage) measured in children aged 24 months:

• the 6-in-1 vaccine was 93.4%, 1.1 percentage points higher than the overall England coverage

• PCV booster was 89%, 1.9 percentage points higher than the overall England coverage

• the MMR1 vaccine was 89.1%, 1.8 percentage points higher than the overall England coverage

• the MenB booster was 88.4%, 1.9 percentage points higher than the overall England coverage

• the Hib/MenC booster coverage was 88.4%, 1.9 percentage points higher than the overall England coverage

In Scotland and Wales, coverage was above 91% for all antigens at 24 months, except for the Hib/MenC booster in Wales which was 90.6%. In Northern Ireland coverage was above 84% for all antigens.

Compared to the previous quarter, MMR1 coverage decreased in all regions. It decreased by:

• 0.2 percentage points in the East of England
• 0.4 percentage points in London
• 0.7 percentage points in the Midlands
• 0.6 percentage points in the North East and Yorkshire
• 0.5 percentage points in the North West
• 0.3 percentage points the South East
• 0.3 percentage points in the South West

Coverage varies by geography. Full coverage data by country, region, and UTLA is contained in the data tables accompanying this report.

Coverage for the MMR1 vaccine for quarter 4 2025 to 2026 by UTLA measured at 24 months is presented in Figure 4.

Figure 4. Coverage of MMR1 vaccine measured in children aged 24 months in England for quarter 4 2025 to 2026 by UTLA

Source of vaccine coverage data: UK Health Security Agency.

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0 Contains OS data © Crown copyright and database right 2025.

Coverage of the MMR vaccine measured at 24 months varies by UTLA. The data underlying Figure 4 is available in the accompanying data file.

In England over the last 10 years, coverage of the 6-in-1 peaked in quarter 2 of 2017 to 2018 at 95.3%, 3.0 percentage points higher than the current quarter coverage of 92.3% (Figure 5a). MMR1 peaked in quarter 3 of 2016 to 2017 at 91.6%, 4.3 percentage points higher than the current quarter coverage of 87.3% (Figure 5b). Coverage of the PCV booster peaked in quarter 3 of 2016 to 2017 at 91.5%, 4.4 percentage points higher than the current quarter coverage of 87.1% (Figure 5c); the Hib/MenC booster peaked in quarter 3 of 2016 to 2017 at 91.6%, 5.1 percentage points higher than the current quarter coverage of 86.5% (Figure 5d); the MenB booster peaked in quarter 2 of 2020 to 2021 at 89.5%, 3.0 percentage points higher than the current quarter coverage of 86.5% (Figure 5e).

Figure 5a. Coverage of the primary course of the 6-in-1 vaccine in England measured at 24 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026 [note 1]

Note 1: the 5-in-1 (DTaP/IPV/Hib3) vaccine was used prior to August 2017 when it was replaced with the 6-in-1 vaccine (DTaP/IPV/Hib/HepB3). As a result, from quarter 4 of 2018 to 2019, coverage of the 6-in-1 vaccine is reported rather than the 5-in-1.

Figure 5b. Coverage of the MMR1 in England measured at 24 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Figure 5c. Coverage of the PCV booster in England measured at 24 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Figure 5d. Coverage of the Hib/MenC booster in England measured at 24 months between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Figure 5e. Coverage of the MenB booster in England measured at 24 months between quarter 3 2017 to 2018 and quarter 4 2025 to 2026

Based on the 2025 IMD scores at the UTLA level, in the 30 least deprived UTLAs, coverage of MMR decreased by 0.2 percentage points to 90.6%. In the 30 most deprived UTLAs, coverage of MMR also decreased by 0.2 percentage points to 82.7%, 7.9 percentage points lower than the 30 least deprived UTLAs. The difference in coverage between these groups has been increasing in the last 6 years, with coverage in the the least deprived group remaining relatively stable and coverage in the most deprived group decreasing (Figure 6a).

Figure 6a. Coverage of the MMR1 vaccine in the 30 most and least deprived local authorities in England, measured at 24 months

For the 6-in-1, the gap has remained relatively stable over time, though in recent quarters it has decreased more in the most deprived UTLAs. Coverage in the most deprived UTLAs dropped by 0.4 percentage points, while in the least deprived UTLAs it dropped by 0.1 percentage points (Figure 6b).

Figure 6b. Coverage of the primary course of the 6-in-1 vaccine in the 30 most and least deprived local authorities in England, measured at 24 months

Coverage at 5 years

For the 6-in-1 vaccine, coverage in the UK increased by 0.2 percentage points to 93.7%, and MMR1 increased by 0.2 percentage points to 92.8%. Hib/MenC coverage increased by 0.4 percentage points to 90.5%. Coverage at 5 years for these vaccines primarily reflects vaccinations delivered 4 years ago.

MMR2 and the preschool booster (dTaP/IPV) are given from the age of 3 years and 4 months and reflect vaccinations that should have been delivered between May 2024 to July 2024.

MMR2 coverage increased by 0.1 percentage points to 84.6% and the dTaP/IPV booster increased by 0.7 percentage points to 83.5%.

Coverage in England measured in children aged 5 years:

• increased by 0.2 percentage points to 93.4% for the 6-in-1 vaccine

• increased by 0.2 percentage points to 92.5% for the MMR1 vaccine

• increased by 0.3 percentage points to 84.1% for the MMR2 vaccine

• increased by 0.5 percentage points to 90.0% for the Hib/MenC vaccine

• increased by 0.9 percentage points to 82.7% for the dTaP/IPV booster vaccine

Coverage in England excluding London (as this was the region with the lowest coverage) measured in children aged 5 years:

• 6-in-1 coverage was 94.5%, 1.1 percentage points higher than the overall England coverage

• MMR1 was 93.9%, 1.4 percentage points higher than the overall England coverage

• MMR2 was 86.9%, 2.8 percentage points higher than the overall England coverage

• Hib/MenC booster coverage was 91.8%, 1.8 percentage points higher than the overall England coverage

• dTaP/IPV booster coverage was 85.6%, 2.9 percentage points higher than the overall England coverage

Both Scotland and Wales exceeded the 95% WHO target for coverage for both the 6-in-1 and MMR1 vaccines measured for children aged 5 years, while coverage in Northern Ireland was above 92%.

Compared to the previous quarter, MMR1 coverage decreased in the North West (0.5 percentage points). There was an increase in MMR1 coverage in the East of England (0.4 percentage points), London (0.3 percentage points), the North East and Yorkshire (0.4 percentage points), and the South East (0.7 percentage points).

MMR1 coverage was stable in the Midlands and the South West.

Coverage of MMR2 also decreased in the North West (0.6 percentage points). Coverage of MMR2 increased in the East of England (0.3 percentage points), London (0.4 percentage points), the Midlands (0.1 percentage points), the North East and Yorkshire (0.4 percentage points), the South East (0.3 percentage points), and the South West (0.1 percentage points).

Coverage varies by geography. Full coverage data by country, region, and UTLA is contained in the data tables accompanying this report.

Coverage for the MMR2 vaccine for quarter 4 2025 to 2026 by UTLA measured in children aged 5 years is presented in Figure 7.

Figure 7. Coverage of MMR2 vaccine measured in children aged 5 years in England for quarter 4 2025 to 2026 by UTLA.

Source of vaccine coverage data: UK Health Security Agency.

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0 Contains OS data © Crown copyright and database right 2025.

Coverage of the MMR2 vaccine measured at children aged 5 years varies by UTLA. The data underlying Figure 7 is available in the accompanying data file.

In England over the last 10 years, coverage of the 6-in-1 vaccine peaked in quarter 2 of 2017 to 2018 at 96.0%, 2.6 percentage points higher than the current quarter coverage of 93.4% (Figure 8a). MMR1 peaked in quarter 1 of 2017 to 2018 at 95.6%, 3.1 percentage points higher than the current quarter coverage of 92.5% (Figure 8b), and MMR2 peaked in quarter 3 of 2016 to 2017 at 87.8%, 3.7 percentage points higher than the current quarter coverage of 84.1% (Figure 8c). Coverage of the dTaP/IPV booster peaked in quarter 2 of 2017 to 2018 at 86.6%, 3.9 percentage points higher than the current quarter coverage of 82.7% (Figure 8d), and coverage of the Hib/MenC booster peaked in quarter 2 of 2017 to 2018 at 93.1%, 3.1 percentage points higher than the current quarter coverage of 90.0% (Figure 8e).

Figure 8a. Coverage of the primary course of the 6-in-1 vaccine in England measured at 5 years between quarter 1 2016 to 2017 and quarter 4 2025 to 2026 [note 1]

Note 1: the 5-in-1 (DTaP/IPV/Hib3) vaccine was used prior to August 2017 when it was replaced with the 6-in-1 vaccine (DTaP/IPV/Hib/HepB3). As a result, from quarter 4 of 2018 to 2019, coverage of the 6-in-1 vaccine is reported rather than the 5-in-1.

Figure 8b. Coverage of MMR1 in England measured at children aged 5 years between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Figure 8c. Coverage of MMR2 in England measured at children aged 5 years between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Figure 8d. Coverage of pre-school booster (dTaP/IPV) in England measured at children aged 5 years between quarter 1 2016 to 2017 and quarter 4 2025 to 2026

Figure 8e. Coverage of the Hib/MenC booster in England measured at children aged 5 years between quarter 1 2016 to 2017 to 2015 and quarter 4 2025 to 2026

Based on the 2025 IMD scores at the UTLA level, in the 30 least deprived UTLAs, coverage of MMR2 increased by 0.5 percentage points to 88.0%. In comparison, in the 30 most deprived UTLAs, coverage of MMR2 decreased by 0.9 percentage points to 77.4%, 10.6 percentage points lower than the 30 least deprived UTLAs (Figure 9a).

Figure 9a. Coverage of the MMR2 vaccine in the 30 most and least deprived local authorities in England, measured at 5 years

Similarly, coverage of the 6-in-1 vaccine in the 30 least deprived UTLAs increased by 0.5 percentage points to 95.2% while it decreased by 0.3 percentage points to 90.3% in the 30 most deprived UTLAs (Figure 9b). The difference in coverage between these groups has been increasing in the last 6 years, with coverage in the least deprived group remaining relatively stable and coverage in the most deprived group decreasing.

Figure 9b. Coverage of the primary course of the 6-in-1 vaccine in the 30 most and least deprived local authorities in England, measured at children aged 5 years

Children aged 5 years in this quarter were born in quarter 4 2020 to 2021. Aged 12 months, coverage for the 6-in-1 was 91.9%. By 24 months it was 93.0%. This current quarter, for children aged 5 years, coverage of the 6-in-1 vaccine is 93.4%. When compared with recent birth cohorts, coverage has increased at each measurement point and has been consistently higher (Figure 10). Birth cohorts over time do not necessarily include the same children due to population movement.

Figure 10. Coverage of the 6-in-1 vaccine across England measured in children aged 5 years when they were aged 12 months, 24 months, and 5 years

Coverage in unregistered children in London

Due to uncertainty in the numbers of children not registered with GPs, these figures for London are reported separately. For antigens measured in these children aged 12 months, coverage was 13.5% for the 6-in-1, 15.5% for MenB, 18.8% for PCV1, and 19.2% for rotavirus. For antigens measured in these children aged 24 months, coverage was 33% for the 6-in-1, 9.1% for MMR1, 8.9% for the Hib/MenC booster, 9.7% for the PCV booster, and 8.6% for the MenB booster. For antigens measured in these children aged 5 years, coverage was 47.1% for the 6-in-1, 4.9% for the dTaP/IPV booster, 29.5% for the Hib/MenC booster, 31.9% for MMR1, and 7.5% for MMR2.

These results should be considered in light of the uncertainty in the numbers of children not registered with GPs and are likely to underestimate true coverage in this group.

Neonatal hepatitis B vaccine coverage: England

National coverage at 12 months for 5 doses of a HepB-containing vaccine increased by 3.1 percentage points to 93.4% compared with the previous quarter (as seen in the previous quarterly report). Coverage of 6 doses of a HepB-containing vaccine reported for children who reached 2 years of age in the quarter (those born January to March 2024) decreased by 5.0 percentage points to 89.6% compared with the last quarter (94.6%) (see the data tables accompanying this report).

The quality of neonatal HepB vaccine data is variable and coverage by regions can be based on small numbers. As such, comparisons of percentages should be considered alongside denominators. Where an area reported no vaccinated children, a check was made to ensure that this was zero reporting rather than absence of available data.

Neonatal BCG vaccine coverage: England

The data captures BCG coverage at the age of 3 months for children born October to December 2025 and at the age of 12 months for children born January to March 2025; it was provided for all local authorities in England and is published in the data tables accompanying this report. Measured at children aged 3 months, coverage in England was 78.0% and measured at 12 months, it was 84.7%.

Glossary

Eligible population

Eligible population is defined as the total number of children in the local authority responsible population reaching their first, second or fifth birthday in the reporting period (see the quality and methodology information report for definition of ‘local authority responsible population’). Coverage is calculated for 3 separate cohorts (children reaching their first, second and fifth birthdays in the reporting period) and so the eligible population differs for each cohort.

Reporting years

Reporting years are financial years (1 April to 31 March) rather than calendar years.

Coverage

Coverage is defined as the number of persons immunised as a proportion of the eligible population. The calculation of coverage is the total number of people immunised divided by the total number eligible in the population and multiplied by 100.

Data sources and methodology

Please see the quality and methodology information report for more information on all the reports.

Data was received from all health boards in Wales, Scotland and Northern Ireland. In England, local teams and Child Health Record Departments provided data for all UTLAs and the associated general practices.

In this report and the accompanying data set, Hackney is included in the City of London, and the Isles of Scilly is included in Cornwall. For selective programmes, Rutland is included in Leicestershire. Cumbria is now reported as Cumberland and Westmorland and Furness.

Coverage statistics should be considered in light of the uncertainty in the numbers of children recorded in child health information systems nationally. This uncertainty is linked to population movement and is therefore likely to have greater impact in urbanised areas with higher levels of population turnover such as London. Coverage may be underestimated in these areas and reported falls in coverage over time should be interpreted with caution due to the relationship with underlying trends in population movement. Work is underway to better understand the scale and impact of population errors on reported coverage to ensure they are consistent and comparable over time and between regions. 

These statistics are subject to both scheduled revisions and unscheduled corrections and are therefore marked as provisional. In addition to correction of any errors made during the production of these statistics, unscheduled corrections also include the correction of errors later identified within the source data received by UKHSA. Revisions and corrections are made timely and transparently in line with UKHSA’s published Revisions and corrections policy.

Additional reference data was sourced from the English indices of deprivation 2025. The Index of Multiple Deprivation (IMD) score at the upper tier local authority-level was extracted. Where upper tier local authorities are combined in this report and the accompanying data set, the score was recalculated for the combined area weighted based on eligible population. The update to the quality and methodology information report, reflecting the addition of IMD data, will be published alongside the quarter 1 (April to June) 2026 report scheduled for 24 September 2026.

Background information

This publication is released on a quarterly basis and aligns with financial quarters. The analysis follows this pattern; any discussion of quarters aligns with the financial year where quarter 1 starts in April.

Children who reached their first birthday in this quarter would have been scheduled to receive their primary course (third dose) of the combined diphtheria, tetanus, acellular pertussis vaccine, inactivated poliomyelitis vaccine, haemophilus influenzae type b vaccine and hepatitis B vaccine (DTaP/IPV/Hib/HepB3 or 6-in-1 vaccination) which protects against diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenzae type b (Hib) and hepatitis B, and their primary course (second dose) of MenB vaccine which protects against meningococcal group B disease at the age of 16 weeks, May 2025 to July 2025. They would have also been scheduled to receive a single dose of PCV (protecting against pneumococcal disease) and 2 doses of rotavirus vaccine at age 12 weeks, April 2025 to June 2025.

Except for the rotavirus vaccine which is only offered up to 6 months of age, all other vaccines are available to children in the current cohort at any time and would have been captured in this report if given by their first birthday. Children born to hepatitis B surface antigen (HBsAg) positive mothers who reached their first birthday in this quarter should also have received monovalent hepatitis B vaccine at birth and at 4 weeks of age.

Children who reached their second birthday would have been scheduled to receive their primary course (third dose) of the 6-in-1 vaccination May 2024 to July 2024 and their first MMR vaccination, a Hib/MenC booster (protecting against haemophilus influenzae type b and meningococcal group C disease), MenB booster and PCV booster at one year of age January 2025 to March 2025. Children born to HBsAg positive mothers, who reached their second birthday in this quarter (born January to March 2024), were scheduled to receive a third dose monovalent hepatitis B vaccine at one year of age.

Children who reached their fifth birthday would have been scheduled to receive their primary course (third dose) of the 6-in-1 vaccination May 2021 to July 2021, their first MMR and the Hib/MenC booster January 2022 to March 2022, their pre-school diphtheria, tetanus, acellular pertussis and polio (dTaP/IPV) booster, and second-dose MMR from May 2024 to July 2024.

Children born in areas where the TB incidence is greater than or equal to 40 per 100,000 or who are born to parents or grandparents from TB endemic areas were eligible for a BCG vaccination at 28 days. Coverage is measured at 3 months of age and 12 months of age for this selective immunisation.

The full routine immunisation schedule sets out the schedule for all childhood immunisations.

Related statistics

• Quarterly childhood vaccination coverage data for England

• Annual childhood vaccination coverage data for England

• Childhood immunisation uptake data for Wales

• Childhood immunisation statistics for Scotland

• Childhood vaccination coverage statistics for Northern Ireland

Further information and contact details

The submission and publication dates for this report series are available, as are additional information for immunisation practitioners and other health professionals.

For any questions or comments regarding this report, please email cover@ukhsa.gov.uk

Official statistics

Our statistical practice is regulated by the Office for Statistics Regulation (OSR). OSR sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to. You can contact OSR by emailing regulation@statistics.gov.uk or via the OSR website.

UKHSA is committed to ensuring that these statistics comply with the Code of Practice for Statistics. This means users can have confidence in the people who produce UKHSA statistics because our statistics are robust, reliable and accurate. Our statistics are regularly reviewed to ensure they support the needs of society for information.

UKHSA has conducted a formal review of these statistics. Following this review, an implementation plan has been developed to continue to improve the trustworthiness, quality, and value of these statistics. Key continuous improvements made will be highlighted within future releases of these statistics for transparency.